GSK:LON
GSK plc
GBXÂ 1,752.00
arrow_upward
+0.95%(+16.50) 1D
Oct 9, 5:03:57 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBXÂ 1,752.00
High
GBXÂ 1,771.50
Low
GBXÂ 1,748.00
Mkt. cap
92.69B
Avg. vol.
5.93M
Volume
6.85M
Dividend
3.88%
Quarterly dividend
GBXÂ 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
14.85
52-wk high
GBXÂ 2,282.00
52-wk low
GBXÂ 1,592.00
EPS
GBXÂ 1.18
Shares outstanding
4.32B
No. of employees
67K
Open
GBXÂ 1,752.00
High
GBXÂ 1,771.50
Low
GBXÂ 1,748.00
Mkt. cap
92.69B
Avg. vol.
5.93M
Volume
6.85M
Dividend
3.88%
Quarterly dividend
GBXÂ 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
14.85
52-wk high
GBXÂ 2,282.00
52-wk low
GBXÂ 1,592.00
EPS
GBXÂ 1.18
Shares outstanding
4.32B
No. of employees
67K
News stories
From web sources and news partners
The Business Journals
·
1 hour ago
GSK commits $800M for construction of new Upper Merion facility as pharma investment surges
AD HOC NEWS
·
2 hours ago
GSK stock trades at EUR 20.81 with USD 93.2 billion value
Yahoo Finance
·
4 hours ago
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
Traders Union
·
8 hours ago
What's behind GSK's latest stock surge?
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com